NEW YORK (GenomeWeb) – Methylation microarrays could provide a simpler and easier way to screen for fragile X syndrome, at least as a first-line option in male patients suspected of having the disorder, according to a new study by researchers from the London Health Sciences Center in Ontario.

Because of the breadth of array-based analysis, this new approach could also offer clinicians the ability to simultaneously screen for multiple different disorders that have overlapping symptoms with fragile X by distinguishing unique methylation signatures associated with each.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.